IGT Joins House Budget Committee Health Care Task Force Roundtable on Cell and Gene Therapies

On Friday, June 28, the House Budget Committee Health Care Task Force hosted a roundtable entitled, “Paying for 21st Century Cures: Examining the Budgetary Effects of Increasing Patient Access to Cell and Gene Therapies.”

IGT's Executive Director Mike Capaldi participated in the critical discussion along with Task Force Chair Michael C. Burgess M.D. (R-TX), Congressional Budget Office (CBO) Director of the Health Analysis Chapin White, FDA's Center for Biologics Evaluation and Research Director Dr. Peter Marks, and Morgan Health CEO Dan Mendelson.

Photo : [From left to right] Dr. Peter Marks (FDA), Chapin White (CBO), Dan Mendelson (Morgan Health), and Mike Capaldi (Institute for Gene Therapies) Credit: House Budget Committee

The discussion focused on the budgetary promise of gene therapies due to their unique transformative nature and the importance of ensuring patient access to these therapies. IGT will continue to advocate for a more modernized healthcare system to better support innovation in this field.

To learn more about the roundtable, click here. To learn more about IGT's policy priorities, click here.